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Abstract
Zika virus (ZIKV) is a mosquito-borne pathogen causing a febrile illness with arthralgia, con-
junctivitis and rash. The complications include Guillain-Barre´ syndrome, congenital brain
and other abnormalities and miscarriage. The serodiagnosis of ZIKV infection is hampered
by cross-reactivity with other members of the Flavivirus family, notably dengue (DENV).
This report describes a novel serological platform for the diagnosis of ZIKV infection. The
approach utilizes time-resolved Fo¨rster resonance energy transfer (TR-FRET) elicited by
two chromophore-labeled proteins (a ZIKV antigen and a super-antigen) simultaneously
binding to a given antibody molecule. The antigen used in the assay is ZIKV non-structural
protein 1 (NS1) and the super-antigen is bacterial protein L. Three assay variants were
developed: the first measuring all anti-ZIKV-NS1 antibodies (LFRET), the second measur-
ing IgM and IgA (acute-LFRET) and the third measuring IgG (immunity-LFRET). The assays
were evaluated with a panel of samples from clinical ZIKV cases in travelers (n = 25) and
seronegative (n = 24) samples. DENV (n = 38), yellow fever (n = 16) and tick-borne-enceph-
alitis (n = 20) seropositive samples were examined for assessment of flavivirus cross-reac-
tivity. The diagnostic sensitivities of the respective LFRET assays were 92%, 100% and
83%, and the diagnostic specificities 88%, 95% and 100% for LFRET, acute-LFRET and
immunity-LFRET. Furthermore, we evaluated the assays against a widely-used commercial
ELISA. In conclusion, the new FRET-based serological approaches based on NS1 protein
are applicable to diagnosing zika virus infections in travelers and differentiating them from
other flavivirus infections.
Introduction
The rapid and accurate diagnosis of the causative agent is the first step in effective manage-
ment of infectious disease. Many agents have similar symptoms and without clear laboratory
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diagnostics the therapeutic interventions can be easily misdirected. A case in point is the Zika
virus epidemic, where several viruses circulate in the same areas with similar outward symp-
toms. The Zika virus (ZIKV) is a mosquito-borne pathogen initially isolated in 1947 in
Uganda. Since then only sporadic cases of ZIKV infection with mild clinical manifestations
were reported in Africa and Southeast Asia [1]. However, in 2007 an outbreak of febrile illness
associated with rash and arthralgia occurred in the Yap island of Micronesia. The causative
agent was found to be ZIKV, and retrospective serological diagnostics demonstrated 73% of
the residents to be ZIKV seropositive [1]. During the following years ZIKV gradually spread
throughout the Micronesian archipelago and made its way to the western hemisphere, with
the first outbreak reported in Bahia, Brazil, 2015 [2]. Thereafter, ZIKV advanced rapidly across
the South American continent, most severely affecting Brazil with over 220,000 clinically con-
firmed cases by January 2018 [3].
The clinical picture of ZIKV primary infection tends to be mild including rash, headache,
conjunctivitis, arthralgia, myalgia and occasional fever [1]. The symptoms are usually self-lim-
ited with an average duration of three to six days, or the infection may be asymptomatic [1].
On the other hand, ZIKV infection can end up with severe neurological sequelae such as Guil-
lain-Barre´ syndrome [4]. Furthermore, clinical and epidemiological studies have confirmed a
causal relationship between ZIKV infection during pregnancy and severe congenital abnor-
malities, such as microcephaly [5, 6].
ZIKV belongs to the family Flaviviridae along with several other important arboviral patho-
gens, such as dengue virus (DENV), yellow fever virus (YFV), tick-borne encephalitis virus
(TBEV) and West Nile virus (WNV). Flaviviruses have a single-stranded, positive-sense RNA
genome of ~11 kilobases (kb). The genome has a single open reading frame encoding three
structural and seven non-structural proteins. The structural proteins (capsid C, envelope E
and matrix M) form the flavivirus particle while the non-structural proteins (NS1, NS2a,
NS2b, NS3, NS4a, NS4b and NS5) participate in virus replication. Both also play a part in
immune evasion. The E protein is the principal target for neutralizing antibody response [7].
However, a notable portion of the E protein epitopes are shared across different flavivirus spe-
cies, providing a major source of serodiagnostic cross-reactivity [8]. In particular, the DENV E
protein is antigenically so closely related to that of ZIKV that a ZIKV-DENV super serogroup
has been suggested [8]. The NS1 has a wide variety of functions and is relatively conserved also
among flaviviruses [9]. Inside the infected cells, NS1 is present as a dimer and assists in virus
replication and suppression of the interferon response [9]. During replication, NS1 secreted as
a hexamer enters the blood stream, wherein it participates in immune evasion. The detection
of NS1 in serum can be utilized in diagnosis of acute DENV infection [10]. NS1 is a strong
immunogen and during DENV infection gives rise to autoreactive antibodies targeting plate-
lets and endothelial cells [11]. Even though the NS1 of ZIKV and DENV are ~50% identical at
amino acid level and have conserved regions, ZIKV-specific epitopes have also been identified
[12].
The adaptive immune response to primary ZIKV infection is similar to that of most viral
infections with an initial IgM rise within 5–7 days post infection (dpi), followed by IgG
response [13]. The IgM can remain detectable for several months in a person previously naïve
for DENV infection, and the IgG response is thought to provide lifelong immunity; however,
the long-term kinetics of ZIKV antibodies are as yet not well known. The current diagnostics
includes reverse transciption PCR (RT-PCR), neutralization tests, enzyme-linked immunosor-
bent assay (ELISA) and immunofluorescence assays. Diagnosis based on RT-PCR is rather
specific but provides a short diagnostic window, as ZIKV RNA in serum is usually detectable
for only 5 to 8 dpi [13]. ZIKV RNA persists longer in whole blood, excretions and in pregnant
women with an infected fetoplacental system [6, 14, 15]. Serodiagnostics have a significantly
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longer diagnostic window but are prone to antibody cross-reactivity between flavivirus species.
This is especially problematic between DENV and ZIKV since both viruses are found in the
ZIKV epidemic regions, with DENV seroprevalence in many areas exceeding 50%. However,
commercial ELISAs for the detection of IgG/IgM antibodies specifically against ZIKV NS1 are
available [16]. As a rule however, the IgM responses to ZIKV in and acute infection are lacking
in DENV-immune persons [17].
We recently described a novel serodiagnostic approach for acute hantavirus disease based
on time-resolved Fo¨rster resonance energy transfer (TR-FRET) [18]. For the FRET phenome-
non to occur, two light-sensitive molecules (chromophores) must be in very close proximity
(<<10 nm). When the donor chromophore is excited with ultraviolet radiation, the excitation
energy is transmitted to the acceptor which then emits the energy. The excitation and the
emission occur at distinct wavelengths, enabling separation of the signals. Chelated lantha-
nides such as Eu moreover exhibit a delay between the absorption and emission, allowing for
time-resolved (TR) detection. The TR-FRET approach permits measurement from autofluor-
escent materials, including serum. The new approach utilizes the simultaneous binding of
donor-labeled viral antigen and acceptor-labeled protein L, a bacterial superantigen that binds
to immunoglobulin kappa light chain (κ-chain) [19]. When a clinical serum is mixed with the
two antigens directly in solution, the possibly contained virus-specific antibodies bring the
donor and acceptor to close proximity for the TR-FRET fluorescence to arise. We call this
diagnostic principle LFRET, of which a schematic overview is shown in Fig 1.
The rapid spread and serious health implications of ZIKV highlight the need for reliable
diagnostic tools. In this report, we demonstrate a method for ZIKV serodiagnosis using NS1
labelled with chelated Eu as the donor (excitation at 320 nm) and protein L labelled with Alex-
aFluor 647 as the acceptor (emission at 647 nm). We further evaluate the test by separate detec-
tion of the antibody classes and document the suitability of the new assay by comparison with
a commercially available ELISA.
Materials and methods
Clinical samples and ethics statement
The ZIKV-positive samples had been sent for diagnosis at the Bernhard Nocht Institute for
Tropical Medicine (Hamburg, Germany), and originate from Finnish or German travelers.
The reference tests for the ZIKV-positive samples (n = 25) included Euroimmun ELISA, indi-
rect immunofluorescence (IIF), neutralization test and RT-PCR and the results are summa-
rized in Table 1. As seen, for several samples the ELISA and IIF results were inconsistent, most
notably for IgM in 11/25 (36%). Therefore, we adopted strict reference criteria according to
which a sample was considered seropositive only if the two reference results matched. Any
samples with conflicting reference data were considered inconclusive and removed from anal-
ysis. This matter is discussed further in Results.
The negative (no antibodies to flaviviruses (ZIKV, DENV, TBEV)) serum samples as well as
those with antibodies to other flaviviruses (YFV recent vaccinees, acute-phase TBEV or DENV
patients) had been sent to the Helsinki University Central Hospital Laboratory Service (HUS-
LAB, Virology and Immunology, Zoonosis Unit, Helsinki, Finland) for infectious disease sero-
diagnosis. The DENV samples (n = 38) were from Finnish travelers with acute illness, of which
a subset (n = 34) were serotyped by partial sequencing of the NS5 gene. All four DENV sero-
types were included (DENV1-DENV4; n = 16, n = 9, n = 3, n = 6 samples respectively) and
most of the sera (n = 35) were also DENV NS1 antigen positive. The acute-phase TBEV sam-
ples (n = 20) came from Finnish patients and were IgM-positive in μ-capture ELISA [20] and
also had elevated hemagglutination inhibition test titers. The YFV samples (n = 16) were IgG-
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positive post-vaccination controls (live attenuated 17D vaccine). These samples (n = 26) had
been collected in Finland during 2009–2014, before the tropical ZIKV epidemic, and were
assumed ZIKV seronegative. All samples in the negative pool that had an unknown ZIKV sta-
tus were tested with EuroImmun IgM and IgG ELISA tests.
All patient samples and clinical data in the study were fully anonymized. The study was
approved under research permit No. 32/2018 issued 09.03.2018 (latest renewal), §16, granted
by the Hospital district of Helsinki and Uusimaa (Teaching and Research).
Proteins
Recombinant protein L (Thermo Scientific, Pierce Protein Biology Products) was labeled with
AlexaFluor 647 as described [21] to yield AF-protL. Recombinant ZIKV NS1 protein (Native
Antigen Company, Oxfordshire, UK) was labeled according to the manufacturer’s instruction
with europium (Eu), using the Quick-AIIAssay Eu-chelated protein labeling kit (BN Products
& Services Oy) to yield Eu-NS1. The degree of labeling, as measured according to the manufac-
turers’ instructions, was 3–4 AF per molecule for protein L and 4.2–5.1 Eu per molecule for
NS1.
Test protocol
Immunoglobulin class-independent ZIKV LFRET. The protocol is modified from previ-
ous [21]. All dilutions were done in Tris-buffered saline (50 mM Tris-HCl, 150 mM NaCl)
supplemented with 0,5% (w/v) BSA (TBS-BSA). The reactions were performed as follows: 5 μl
of AF-protL (50 nM) and 5 μl of Eu-NS1 (20 nM) were mixed on 384-well microplate (Proxi-
Plate-384 Plus F; black 384-shallow-well microplate from PerkinElmer) and 10 μl of 1:50
diluted serum was added and mixed by pipetting. The final concentrations in the final 20 μl
reaction volume were serum diluted 1:100, 25 nM AF-protL, and 10 nM Eu-NS1. After com-
bining the constituents, the LFRET values were immediately measured with a Victor Wallac2
Fig 1. The LFRET assay principle. The Eu-labeled antigen (ZIKV NS1), Alexa-Fluor-labeled protein L and the serum sample are mixed together in a
384-well microplate. The former binds to the light chains of the antibodies, which if ZIKV-NS1-specific also bind the europium-labeled NS1 antigen.
The mixture is exposed to UV light and the close proximity allows the donor and acceptor to elicit the FRET signal, which is measured.
https://doi.org/10.1371/journal.pone.0219474.g001
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fluorometer (PerkinElmer), normalized and presented as integers (the LFRET count) as earlier
[18, 22]. All measurements were performed in duplicate.
Class-specific ZIKV LFRET. To separate the TR-FRET counts induced by antibodies of
distinct immunoglobulin classes, we developed two variants of the class-independent assay.
For detection of acute infections the IgG antibodies were removed by mixing the serum 1:10
with GullSORB (Meridium Bioscience, USA) and centrifugation at 16,000 x g for 10 s. The
supernatant was diluted 1:5 with TBS-BSA yielding a final dilution of 1:50, which was used in
the assay described above. For IgG detection the IgM antibodies in the samples were inacti-
vated as described [23]. Briefly, the sera were diluted 1:50 with TBS-BSA containing 5 mM
dithiothreitol (TBS-DTT) and incubated for 2 h at +37 ˚C. The dilutions were then used as
above.
Results
Immunoglobulin class-independent LFRET against ZIKV
To set up the assay, we performed cross-titration experiments using pooled ZIKV seropositive
and seronegative sera at various concentrations of Eu-labelled ZIKV-NS1 (Eu-NS1) and Alexa-
Fluor-labeled protein L (AF-ProtL) and concluded the optimal concentrations of the reagents
Table 1. Reference test results for ZIKV-positive samples.
Patient pseudonym Sample # Days from onset ZIKV PCRa ZIKV ELISA ZIKV IIF DENV IIF
IgG IgM IgG IgM IgG IgM
Z1 1 65 neg pos neg 640 20 - - - -
" 2 118 neg pos neg 160 20 - - - -
" 6 308 - - pos pos 1280 neg - - - -
" 8 407 - - pos neg 320 neg - - - -
Z2 1 38 neg pos neg 5120 80 2560 neg
" 3 434 - - pos neg 2560 neg 640 neg
Z3 1 35 neg pos pos 20480 80 1280 neg
" 3 426 - - pos neg 5120 neg 2560 neg
Z4 1 16 pos pos pos 2560 1280 80 neg
" 3 52 - - pos pos 1280 160 1280 neg
" 4 115 - - pos neg 1280 40 80 n.T.
Z5 1 7 pos pos pos 5120 5120 80 neg
" 4 100 - - pos neg 640 320 80 n.t.
Z6 1 19 pos pos pos 5120 40 5120 neg
Z7 1 11 pos pos pos 5120 1280 5120 neg
31 1 N/A - - neg pos 640 neg - - - -
188 1 N/A - - neg pos 20480 neg - - - -
229 1 N/A - - pos pos pos pos - - - -
354 1 N/A - - pos pos pos pos - - - -
595 1 N/A - - pos neg pos pos 80 20
775 1 N/A - - neg pos neg neg - - - -
864 1 N/A pos neg pos pos pos 1280 neg
901 1 N/A - - neg pos pos pos - - - -
948 1 N/A - - pos pos pos pos 20480 80
956 1 N/A - - neg neg pos pos - - - -
aPCR from either urine or blood
https://doi.org/10.1371/journal.pone.0219474.t001
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to be 20 nM and 50 nM, respectively. With these test parameters, we analyzed a cohort of
ZIKV ELISA IgG- or IgM-positive samples (from patients Z1-Z7, n = 15) together with a panel
of ZIKV seronegative samples (n = 24). The average LFRET count (AVG) for negative samples
was 20.8 with a standard deviation (SD) of 12.8. From this data, we initially set a cut-off for
positivity at AVG + 2.5�SD, LFRET count of 52.8. All of the 15 samples known to be positive
had LFRET counts above this cut-off and their detailed results are shown in Fig 2.
Since flavivirus serodiagnostics are known to suffer from inter-species cross-reactivity, we
then analyzed a panel of well-characterized sera representing acute infections with DENV
(n = 38) and TBEV (n = 20) and YFV vaccinees (n = 16) as well as additional negative samples
(n = 2) and cases of ZIKV (n = 10) with LFRET. The combined results (Fig 3) showed only
minor cross-reactivity by the other flaviviruses with ZIKV. After reviewing the data, we
adjusted the cut-off value for positivity to LFRET count 57, corresponding to AVG + 2.8�SD.
Including all sample categories the assay had a sensitivity of 92%. The specificity in the heterol-
ogous flavivirus seropositive samples was 87% (88% for DENV and 87% for YFV), and 100%
among flavivirus seronegative samples. The test outcomes of all sample types are presented in
Table 2 and the complete result set is presented in S1 Table.
Class-specific LFRET assays
The LFRET assay is based on the simultaneous binding of protein L and the antigen to the
same antibody, and the LFRET counts measured from human serum can be derived from any
Ig class. As such, further analysis of the samples was required to see whether the LFRET test
could be utilized to distinguish between signals induced by IgM and IgG. To measure the
Fig 2. Class-independent LFRET scores for the first cohort of samples.
https://doi.org/10.1371/journal.pone.0219474.g002
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counts induced by antibodies other than IgG, ie. to detect acute infection, we depleted IgG
from the samples using GullSORB reagent. Following IgG depletion, the ZIKV-specific LFRET
signals from serum are induced by IgM and IgA (also to a lesser degree IgE). To determine
immunity by measuring ZIKV-specific IgG, we inactivated IgM antibodies from the samples
using 5 mM DTT. Given that IgA antibodies are more resistant to DTT than IgM and not fully
inactivated in this protocol [24], this variant can also measure ZIKV-specific IgA. IgE antibod-
ies are rendered inactive with DTT concentrations over 2 mM and hence undetectable [25].
The IgG depletion variant will be referred to as acute-LFRET and the IgM inactivation variant
as immunity-LFRET.
To obtain baseline values for negative samples, we tested a cohort of negative samples with
both class-specific variants. Similarly to class-independent LFRET, we calculated a cut-off for
positivity at AVG + 2.5�SD yielding cut-offs for the acute and immunity assays at 62 and 65,
Fig 3. Class-independent LFRET scores measured from the full panel of ZIKV-positive, heterologous flavivirus-positive
(DENV, YFV or TBEV) and flavivirus-negative samples.
https://doi.org/10.1371/journal.pone.0219474.g003
Table 2. Class-independent LFRET test outcomes in different sample categories.
ZIKV-positive (n = 25) DENV-positive (n = 38) YFV-positive (n = 16) TBEV-positive (n = 20) Negative (n = 26)
LFRET- positive 92% (n = 23) 12% (n = 5) 13% (n = 2) 0% (n = 0) 0% (n = 0)
LFRET- negative 8% (n = 2) 88% (n = 33) 87% (n = 14) 100% (n = 20) 100% (n = 26)
https://doi.org/10.1371/journal.pone.0219474.t002
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respectively. After the preliminary runs we tested all of the remaining samples in both assay
variants and the complete result set is presented in S1 Table.
As stated in Materials and methods, due to the inconsistencies between the reference meth-
ods (Table 1) we initially deemed the samples seropositive excusively when the two reference
methods agreed. We classified any samples with divergent ELISA and IIF results (n = 11 and
n = 5 for IgM and IgG, respectively) as inconclusive and removed them from statistical analy-
sis. Some of the ZIKV-negative samples were omitted in acute-LFRET (n = 1) and immunity-
LFRET (n = 17) due to shortage of the original material. Based on these criteria the test panel
contained 113 samples for acute-LFRET and 103 samples for immunity-LFRET. The class-spe-
cific LFRET results of this cohort are presented in Fig 4 and Table 3. In both acute-FRET and
immunity-LFRET, cross-reactivity with other flaviviruses played only a minor role, as evi-
denced by the respective specificities of 96% and 100%, at sensitivities of 100% and 95%. Inter-
estingly, both of the class-specific assays showed significantly higher specificity than the class-
independent LFRET (specificity 88%).
We next carried out a assay evaluation including all samples positive in either ELISA or IIF,
or both. The acute- and immunity-LFRET results based on these criteria are presented in
Table 4. The inclusion of these looser criteria did not alter the sensitivity or specificity (100%
and 96%) of the acute-LFRET. On the other hand, while the specificity of the immunity-
LFRET remained at 100%, its sensitivity decreased to 83%.
Fig 4. a) Acute-LFRET scores of IgM-positive and -negative samples b) Immunity-LFRET scores of IgG-positive and -negative samples.
https://doi.org/10.1371/journal.pone.0219474.g004
Table 3. Test outcomes in class-specific LFRET tests compared with the reference tests.
a) Anti-ZIKV-IgM-positive
(n = 11)
Anti-ZIKV-IgM-negative
(n = 102)
b) Anti-ZIKV-IgG-positive
(n = 19)
Anti-ZIKV-IgG-negative
(n = 84)
Acute-LFRET
positive
100% (n = 11) 4% (n = 4) Immunity-LFRET
positive
95% (n = 18) 0% (n = 0)
Acute-LFRET
negative
0% (n = 0) 96% (n = 98) Immunity-LFRET
negative
5% (n = 1) 100% (n = 84)
a) Acute-LFRET outcomes vs. IgM-reference tests
b) Immunity-LFRET outcomes vs. IgG-reference tests
https://doi.org/10.1371/journal.pone.0219474.t003
Immunoassay for serodiagnosis of Zika virus infection
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Comparison of LFRET with a commercial ELISA
We compared the performance of the new assay to a commercially available ZIKV NS1-based
IgM and IgG ELISAs (Euroimmun, Germany) [16] using a subset of the samples. The subset
consisted of all the ZIKV-positives (by any reference test, n = 25) as well as some DENV-
(n = 23) and YFV-positives (n = 10) and all samples that had cross-reacted in any of the three
LFRET assay variants.
To analyze the results we compared the optical density (OD) values measured in the ELISAs
with the LFRET scores for each sample (Fig 5). These results are listed in S2 and S3 Tables.
There was a moderate correlation between the immunity-LFRET scores and the IgG ELISA
ODs (correlation coefficient r = 0.68). However, the acute-LFRET scores correlated strongly
with the corresponding IgM ELISA ODs (r = 0.85). In Student’s t-test both correlations were
highly significant (p<0.001).
Following the observation that the LFRET and ELISA assays were correlated in terms of the
measured values, we then compared their binary outcomes (positive / negative). The IgM and
IgG outcome comparison is presented in Table 5. Despite the overall good correlation, the
LFRET and ELISA outcomes of several samples diverged, especially for IgM, and these results
are listed in Table 6. In the majority of such cases (9/12), the LFRET and IIF were positive
while the ELISA was negative.
Discussion
Herein we describe a simple TR-FRET-based homogenous serological assay for ZIKV infec-
tion. We examined a panel of 25 ZIKV-antibody positive travelers’ samples, a cohort of sam-
ples with another clinical flaviviral infection or recent vaccination and seronegatives. We
developed three variants of the assay and showed a diagnostic specificity and sensitivity of
higher than 90% in all variants.
Cross-reactivity has traditionally been a major problem in the serodiagnosis of flaviviruses
since the different species are antigenically closely related. Many flaviviruses also co-circulate
and pre-existing immunity towards at least one member of the genus is frequently a confound-
ing factor in serological diagnosis. Because of this, we included several samples with heterolo-
gous flaviviral infections to the test panel. DENV is antigenically very similar to ZIKV and
widely endemic with high seroprevalence and it is an important source of cross-reactivity. In
our panel, the samples from acute primary DENV infections gave rise to some false positive
reactivities in the class-independent assay, which in the class-specific assays however remained
absent. Similarly, YFV also elicited some false reactivity in the class-independent assay but
none in the class-specific variants. Overall, cross-reactivity did not significantly hamper the
differentiation of ZIKV-specific antibodies from other flaviviruses. Rapid assessment of ZIKV-
positive sera from DENV-endemic areas in Brazil showed high specificity but lowered
Table 4. Test outcomes when using non-rigorous sample inclusion criteria.
a) Anti-ZIKV-IgM-positive
(n = 22)
Anti-ZIKV-IgM-negative
(n = 102)
b) Anti-ZIKV-IgG-positive
(n = 24)
Anti-ZIKV-IgG-negative
(n = 84)
Acute-LFRET
positive
100% (n = 22) 4% (n = 4) Immunity-LFRET
positive
83% (n = 20) 0% (n = 0)
Acute-LFRET
negative
0% (n = 0) 96% (n = 98) Immunity-LFRET
negative
17% (n = 4) 100% (n = 84)
a) Acute-LFRET outcomes vs. IgM-reference tests
b) Immunity-LFRET outcomes vs. IgG-reference tests
https://doi.org/10.1371/journal.pone.0219474.t004
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sensitivity. The same phenomenon has been observer for other serological tests [18] and fur-
ther experiments with well characterized positive and negative sera form DENV-endemic
areas are needed to assess the usability of this test in DENV-immune individuals.
As noted, in the panel of ZIKV positive samples there were many instances where the refer-
ence tests ELISA and IIF were inharmonious. As no “gold standard” exists in ZIKV serodiag-
nostics, these two reference tests were employed to corroborate each other. Accordingly, a
Fig 5. Euroimmun ELISA vs. class-specific LFRET. a) Optical density values in Euroimmun IgM ELISA compared to the acute-
LFRET scores of the same samples; b) OD values in Euroimmun IgG ELISA test compared to the immunity-LFRET score.
https://doi.org/10.1371/journal.pone.0219474.g005
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sample was considered positive only if both of the two were positive, and the remaining sam-
ples were excluded from evaluation. This diminished the number of samples especially for
IgM (n = 11), and reduced the statistical power. Such strictness of inclusion criteria we consid-
ered essential for the reliability of the reference tests. However, for completeness we also used
an approach where the inclusion criteria was a positive result in either reference test. Even
with this less rigorous sample selection, the assays showed high specificity and sensitivity.
Unlike in the classical serodiagnostics such as ELISA or IIF, in which a single antibody class
is detected at a time, the LFRET follows a different strategy. In class-independent LFRET all
antibody isotypes are detected simultaneously, whereas in the acute and immunity variants
one immunoglobulin class at a time is removed and those that remain are detected. Therefore,
for example, any specific IgA or IgE, which are often otherwise ignored, will be included in the
LFRET result. This will permit the detection of un-orthodox antibody responses (e.g. IgA-
only), and potentially allow for diagnosis with increased sensitivity.
To gauge the performance of LFRET further, we compared the results from the class-spe-
cific assays against Euroimmun ELISA, a commercial kit based on the same antigen, ZIKV
NS1. As stated in Results, the numerical measurements of the assays correlated strongly; how-
ever, the binary outcomes often did not. Looking into these data it was evident that in most
cases the ELISA was negative, while both LFRET and IIF were positive. There are some indica-
tions of this ELISA having a somewhat low sensitivity, e.g. as compared to the combination of
Table 5. Comparison of the outcomes of the Euroimmun ELISA test with class-specific LFRET test outcomes.
a) Euroimmun IgG ELISA
positive
Euroimmun IgG ELISA
negative
b) Euroimmun IgM ELISA
positive
Euroimmun IgM ELISA
negative
Immunity- LFRET
positive
17 3 Acute-LFRET
positive
15 11
Immunity-LFRET
negative
1 33 Acute-LFRET
negative
0 26
a: Outcome of IgG ELISA vs. immunity-LFRET.
b: Outcome of IgM ELISA vs. acute-LFRET.
https://doi.org/10.1371/journal.pone.0219474.t005
Table 6. The samples with inconsistent results between Euroimmun ELISA and class-specific LFRET assay.
Pseudonym Sample # IgM IgG Inconsistent antibody classa LFRET result consistent with IIFb
ELISA LFRET ELISA LFRET
Z1 1 - + + + IgM Yes
" 2 - + + + IgM Yes
" 8 - + + + IgM No
Z2 1 - + + + IgM Yes
" 3 - + + + IgM No
Z3 1 + + - + IgG Yes
Z4 4 - + + + IgM Yes
Z5 1 + + + - IgG No
" 4 - + + + IgM Yes
188 1 + + - + IgG Yes
595 1 - + + + IgM Yes
956 1 - + - + IM and IgG Yes
aThe class of antibody that has an ELISA result inconsistent with the LFRET result.
bIs the LFRET result consistent with the IIF reference results.
https://doi.org/10.1371/journal.pone.0219474.t006
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a CDC-approved IgM antibody capture ELISA and plaque reduction neutralization test [26],
and our data seems to show parallel findings.
The present is the second application of the LFRET approach, the first being developed for
hantavirus disease [18]. Similarly to latter, the ZIKV assay had a diagnostic specificity and sen-
sitivity of>95%. These findings suggest that the wash-free LFRET assay adapted to a point-of-
care setting has potential for assisting in clinical decision-making.
Supporting information
S1 Table. The complete LFRET result listing. This table contains the LFRET test results for
all samples in all of the assay variants.
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